PUBLICATIONS
* indicates members from the Fortier Lab
All PubMed publications HERE.
Google Scholar profile HERE (H-index = 35, i10 index = 42 on January 14, 2023)
ResearchGate profile HERE.
2023
The long and sinuous road to phage-based therapy of Clostridioides difficile infections. Umansky AA*, Fortier LC. Front Med (Lausanne). 2023 Aug 23;10:1259427. doi: 10.3389/fmed.2023.1259427. eCollection 2023.PMID: 37680620
Virulence and genomic diversity among clinical isolates of ST1 (BI/NAP1/027) Clostridioides difficile. Dong Q, Lin H, Allen MM*, Garneau JR*, Sia JK, Smith RC, Haro F, McMillen T, Pope RL, Metcalfe C, Burgo V, Woodson C, Dylla N, Kohout C, Sundararajan A, Snitkin ES, Young VB, Fortier LC, Kamboj M, Pamer EG. Cell Rep. 2023 Aug 29;42(8):112861. doi: 10.1016/j.celrep.2023.112861. Epub 2023 Jul 30.PMID: 37523264
Chronic Diarrhea Caused by a Klebsiella oxytoca Toxin Producer Strain Following Antibiotic-Associated Hemorrhagic Colitis: Successful Treatment by Fecal Microbiota Transplant. Granger MF, Kelly M, Fortier LC, Fournier E, Côté-Gravel J, Malouin F, Valiquette L, Lévesque S. Clin Infect Dis. 2023 Dec 15;77(12):1700-1703. doi: 10.1093/cid/ciad436.PMID: 37477511
Assessment of antibacterial properties and skin irritation potential of anodized aluminum impregnated with various quaternary ammonium. Jann J*, Gascon S*, Drevelle O, Fradette J, Auclair-Gilbert M, Soucy G, Fortier LC, Faucheux N. Biomater Adv. 2023 Jul;150:213433. doi: 10.1016/j.bioadv.2023.213433. Epub 2023 Apr 20.PMID: 37104962
Clostridioides difficile S-Layer Protein A (SlpA) Serves as a General Phage Receptor. Royer ALM*, Umansky AA*, Allen MM*, Garneau JR*, Ospina-Bedoya M*, Kirk JA, Govoni G, Fagan RP, Soutourina O, Fortier LC. Microbiol Spectr. 2023 Feb 15;11(2):e0389422. doi: 10.1128/spectrum.03894-22. Online ahead of print.PMID: 36790200
Virulence and genomic diversity among clinical isolates of ST1 (BI/NAP1/027) Clostridioides difficile. Dong Q, Lin H, Allen MM*, Garneau JR*, Sia JK, Smith RC, Haro F, McMillen T, Pope RL, Metcalfe C, Burgo V, Woodson C, Dylla N, Kohout C, Sundararajan A, Snitkin ES, Young VB, Fortier LC, Kamboj M, Pamer EG. bioRxiv. 2023 Jan 12:2023.01.12.523823. doi: 10.1101/2023.01.12.523823. Preprint.PMID: 36711955
Defects in the expression of colonic host defense factors associate with barrier dysfunction induced by a high-fat/high-cholesterol diet. Valdes J, Gagné-Sansfaçon J, Reyes V, Armas A, Marrero G, Moyo-Muamba M, Ramanathan S, Perreault N, Ilangumaran S, Rivard N, Fortier LC, Menendez A. Anat Rec (Hoboken). 2023 May;306(5):1165-1183. doi: 10.1002/ar.25083. Epub 2022 Oct 5.PMID: 36196983
Interleukin 15 in murine models of colitis. Kautzman AM, Mobulakani JMF, Marrero Cofino G, Quenum AJI, Cayarga AA, Asselin C, Fortier LC, Ilangumaran S, Menendez A, Ramanathan S. Anat Rec (Hoboken). 2023 May;306(5):1111-1130. doi: 10.1002/ar.25044. Epub 2022 Jul 28. PMID: 35899872
2022
The Clostridioides difficile S-Layer Protein A (SlpA) serves as a general phage receptor. Royer ALM*, Umansky AA*, Allen MM*, Garneau JR*, Ospina-Bedoya M*, Kirk JA, Govoni G, Fagan RP, Soutourina O, Fortier LC. BioRxiv 2022.09.19.508581 (2022) doi:10.1101/2022.09.19.508581.
2021
Rapid antibacterial activity of anodized aluminum-based materials impregnated with quaternary ammonium compounds for high-touch surfaces to limit transmission of pathogenic bacteria. Jann J*, Drevelle O, Chen XG, Auclair-Gilbert M, Soucy G, Faucheux N and Fortier LC. RSC Advances., 2021,11, 38172-38188.
Inactivation of the riboswitch-controlled GMP synthase GuaA in Clostridioides difficile is associated with severe growth defects and poor infectivity in a mouse model of infection. Smith-Peter E*, Séguin DL*, St-Pierre É*, Sekulovic O*, Jeanneau S, Tremblay-Tétreault C, Lamontagne AM, Jacques PÉ, Lafontaine DA, Fortier LC. RNA Biol. 2021 Oct 6:1-12. doi: 10.1080/15476286.2021.1978768.
Pathophysiology of Vaginal Erosions in Women Using Pessary: a pilot study examining vaginal microbiota. Bouchard ME, Rousseau E, Fortier LC, Girard I. J Obstet Gynaecol Can. 29:S1701-2163(21)00347-9.
Clostridioides difficile Phage Biology and Application. Heuler J, Fortier LC, Sun X. FEMS Microbiology Reviews. fuab012.
2020
Type I toxin-antitoxin systems contribute to the maintenance of mobile genetic elements in Clostridioides difficile. Peltier J, Hamiot A, Garneau JR*, Boudry P, Maikova A, Hajnsdorf E, Fortier LC, Dupuy B, Soutourina O. Commun Biology 3, 718.
In Vivo Targeting of Clostridioides difficile Using Phage-Delivered CRISPR-Cas3 8Antimicrobials. Selle K, Fletcher JR, Tuson H, Schmitt DS, McMillan L, Vridhambal GS, Rivera AJ, Montgomery SA, Fortier LC, Barrangou R, Theriot CM, Ousterout DG. mBio 11 (2). doi:10.1128/mBio.00019-20.
Type I toxin-antitoxin systems contribute to mobile genetic elements maintenance in Clostridioides difficile and can be used as a counter-selectable marker for chromosomal manipulation. Peltier J, Hamiot A, Garneau JR*, Boudry P, Maikova A, Fortier LC, Dupuy B, Soutourina O. BioRixv.
2019
Multilocus Variable-Number Tandem-Repeat Analysis of Clostridioides difficile Clusters in Ribotype 027 Isolates and Lack of Association with Clinical Outcomes. Garneau JR*, Abou Chakra CN, Fortier LC, Labbé AC, Simor AE, Gold W, Muller M, McGeer A, Powis J, Katz K, Pépin J, Valiquette L. J Clin Microbiol. 2019 Apr 26;57(5). pii: e01724-18.
2018
Bacteriophages Contribute to Shaping Clostridioides (Clostridium) difficile Species. Fortier LC. Front Microbiol. 2018 Aug 31;9:2033.
[Discovery of keyicin, a new antibiotic: it takes two to tango]. Carignan A, Fortier LC. Med Sci (Paris). 2018 May;34(5):377-379.
Purine analogs targeting the guanine riboswitch as potential antibiotics against Clostridioides difficile. Yan LH, Le Roux A, Boyapelly K, Lamontagne AM, Archambault MA, Picard-Jean F, Lalonde-Seguin D*, St-Pierre E*, Najmanovich RJ, Fortier LC, Lafontaine D, Marsault É. Eur J Med Chem. 2018 Jan 1;143:755-768.
High Prevalence and Genetic Diversity of Large phiCD211 (phiCDIF1296T)-Like Prophages in Clostridioides difficile. Garneau JR*, Sekulovic O*, Dupuy B, Soutourina O, Monot M, Fortier LC. Appl Environ Microbiol. 2018 Jan 17;84(3). pii: e02164-17.
2017
The Contribution of Bacteriophages to the Biology and Virulence of Pathogenic Clostridia. Fortier LC. Adv Appl Microbiol. 2017;101:169-200.
Ileal antimicrobial peptide expression is dysregulated in old age. Tremblay S, Côté NML, Grenier G, Duclos-Lasnier G, Fortier LC, Ilangumaran S, Menendez A. Immun Ageing. 2017 Aug 29;14:19.
PhageTerm: a tool for fast and accurate determination of phage termini and packaging mechanism using next-generation sequencing data. Garneau JR, Depardieu F, Fortier LC, Bikard D, Monot M. Sci Rep. 2017 Aug 15;7(1):8292.
A sexually dichotomous, autistic-like phenotype is induced by Group B Streptococcus maternofetal immune activation. Allard MJ, Bergeron JD, Baharnoori M, Srivastava LK, Fortier LC, Poyart C, Sébire G. Autism Res. 2017 Feb;10(2):233-245.
2016
Activation of the IL-1β/CXCL1/MMP-10 axis in chorioamnionitis induced by inactivated Group B Streptococcus. Bergeron J, Gerges N, Guiraut C, Grbic D, Allard MJ, Fortier LC, Vaillancourt C, Sébire G. Placenta. 2016 Nov;47:116-123.
Characterization of Functional Prophages in Clostridium difficile. Sekulović O, Fortier LC. Methods Mol Biol. 2016;1476:143-65.
2015
Erratum for Boudry et al., function of the CRISPR-Cas system of the human pathogen Clostridium difficile. Boudry P, Semenova E, Monot M, Datsenko KA, Lopatina A, Sekulovic O, Ospina-Bedoya M, Fortier LC, Severinov K, Dupuy B, Soutourina O. MBio. 2015 Oct 6;6(5):e01508-15.
Factors Associated With Complications of Clostridium difficile Infection in a Multicenter Prospective Cohort. Abou Chakra CN, McGeer A, Labbé AC, Simor AE, Gold WL, Muller MP, Powis J, Katz K, Garneau JR, Fortier LC, Pépin J, Cadarette SM, Valiquette L. Clin Infect Dis. 2015 Dec 15;61(12):1781-8.
Function of the CRISPR-Cas System of the Human Pathogen Clostridium difficile. Boudry P, Semenova E, Monot M, Datsenko KA, Lopatina A, Sekulovic O, Ospina-Bedoya M, Fortier LC, Severinov K, Dupuy B, Soutourina O. MBio. 2015 Sep 1;6(5):e01112-15.
The Clostridium difficile cell wall protein CwpV confers phase-variable phage resistance. Sekulovic O, Ospina Bedoya M, Fivian-Hughes AS, Fairweather NF, Fortier LC. Mol Microbiol. 2015 Oct;98(2):329-42.
Cyclic di-GMP riboswitch-regulated type IV pili contribute to aggregation of Clostridium difficile. Bordeleau E, Purcell EB, Lafontaine DA, Fortier LC, Tamayo R, Burrus V. J Bacteriol. 2015 Mar;197(5):819-32.
Global transcriptional response of Clostridium difficile carrying the CD38 prophage. Sekulovic O, Fortier LC. Appl Environ Microbiol. 2015 Feb;81(4):1364-74.
2014
Characterization of temperate phages infecting Clostridium difficile isolates of human and animal origins. Sekulovic O, Garneau JR, Néron A, Fortier LC. Appl Environ Microbiol. 2014 Apr;80(8):2555-63.
Prevention of Clostridium difficile spore formation by sub-inhibitory concentrations of tigecycline and piperacillin/tazobactam. Garneau JR, Valiquette L, Fortier LC. BMC Infect Dis. 2014 Jan 15;14:29.
2013
White matter injury and autistic-like behavior predominantly affecting male rat offspring exposed to group B streptococcal maternal inflammation. Bergeron JD, Deslauriers J, Grignon S, Fortier LC, Lepage M, Stroh T, Poyart C, Sébire G. Dev Neurosci. 2013;35(6):504-15.
Importance of prophages to evolution and virulence of bacterial pathogens. Fortier LC, Sekulovic O. Virulence. 2013 Jul 1;4(5):354-65.
2012
Novel high-molecular-weight, R-type bacteriocins of Clostridium difficile. Gebhart D, Williams SR, Bishop-Lilly KA, Govoni GR, Willner KM, Butani A, Sozhamannan S, Martin D, Fortier LC, Scholl D. J Bacteriol. 2012 Nov;194(22):6240-7.
Evidence of in vivo prophage induction during Clostridium difficile infection. Meessen-Pinard M, Sekulovic O, Fortier LC. Appl Environ Microbiol. 2012 Nov;78(21):7662-70.
2011
Lack of association between clinical outcome of Clostridium difficile infections, strain type, and virulence-associated phenotypes. Sirard S, Valiquette L, Fortier LC. J Clin Microbiol. 2011 Dec;49(12):4040-6.
c-di-GMP turn-over in Clostridium difficile is controlled by a plethora of diguanylate cyclases and phosphodiesterases. Bordeleau E, Fortier LC, Malouin F, Burrus V. PLoS Genet. 2011 Mar;7(3):e1002039.
Prophage-stimulated toxin production in Clostridium difficile NAP1/027 lysogens. Sekulovic O, Meessen-Pinard M, Fortier LC. J Bacteriol. 2011 Jun;193(11):2726-34.
2010
Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection. Gonzales M, Pepin J, Frost EH, Carrier JC, Sirard S, Fortier LC, Valiquette L. BMC Infect Dis. 2010 Dec 30;10:363.
Novel riboswitch ligand analogs as selective inhibitors of guanine-related 8metabolic pathways. Mulhbacher J, Brouillette E, Allard M, Fortier LC, Malouin F, Lafontaine DA. PLoS Pathog. 2010 Apr 22;6(4):e1000865.8
2009
Antiapoptotic proteins Bcl-2 and Bcl-XL inhibit Clostridium difficile toxin A-induced cell death in human epithelial cells. Matte I, Lane D, Côté E, Asselin AE, Fortier LC, Asselin C, Piché A. Infect Immun. 2009 Dec;77(12):5400-10.
Phage production and maintenance of stocks, including expected stock lifetimes. Fortier LC, Moineau S. Methods Mol Biol. 2009;501:203-19.
2008
AbiV, a novel antiphage abortive infection mechanism on the chromosome of Lactococcus lactis subsp. cremoris MG1363. Haaber J, Moineau S, Fortier LC, Hammer K. Appl Environ Microbiol. 2008 Nov;74(21):6528-37.
2007
Morphological and genetic diversity of temperate phages in Clostridium difficile. Fortier LC, Moineau S. Appl Environ Microbiol. 2007 Nov;73(22):7358-66.
2006
Genome sequence and global gene expression of Q54, a new phage species linking the 936 and c2 phage species of Lactococcus lactis. Fortier LC, Bransi A, Moineau S. J Bacteriol. 2006 Sep;188(17):6101-14.
The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver. Girard H, Villeneuve L, Court MH, Fortier LC, Caron P, Hao Q, von Moltke LL, Greenblatt DJ, Guillemette C. Drug Metab Dispos. 2006 Jul;34(7):1220-8.
2005
UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxification in the liver. Girard H, Thibaudeau J, Court MH, Fortier LC, Villeneuve L, Caron P, Hao Q, von Moltke LL, Greenblatt DJ, Guillemette C. Hepatology. 2005 Aug;42(2):448-57.
Expression and site-directed mutagenesis of the lactococcal abortive phage infection protein AbiK. Fortier LC, Bouchard JD, Moineau S. J Bacteriol. 2005 Jun;187(11):3721-30.
2004
Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Girard H, Court MH, Bernard O, Fortier LC, Villeneuve L, Hao Q, Greenblatt DJ, von Moltke LL, Perussed L, Guillemette C. Pharmacogenetics. 2004 Aug;14(8):501-15.
2003
Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. Villeneuve L, Girard H, Fortier LC, Gagné JF, Guillemette C. J Pharmacol Exp Ther. 2003 Oct;307(1):117-28. Epub 2003 Aug 27.
Induction of Oenococcus oeni H+-ATPase activity and mRNA transcription under acidic conditions. Fortier LC, Tourdot-Maréchal R, Diviès C, Lee BH, Guzzo J. FEMS Microbiol Lett. 2003 May 28;222(2):165-9.
2000
Regulation of stress response in Oenococcus oeni as a function of environmental changes and growth phase. Guzzo J, Jobin MP, Delmas F, Fortier LC, Garmyn D, Tourdot-Maréchal R, Lee B, Diviès C. Int J Food Microbiol. 2000 Apr 10;55(1-3):27-31.
1999
Acid sensitivity of neomycin-resistant mutants of Oenococcus oeni: a relationship between reduction of ATPase activity and lack of malolactic activity. Tourdot-Maréchal R, Fortier LC, Guzzo J, Lee B, Diviès C. FEMS Microbiol Lett. 1999 Sep 15;178(2):319-26.
1998
Rescue of polyomavirus DNA after co-transfection of recombinant plasmids with viral DNA fragments. Fortier LC, Delbecchi L, Bourgaux-Ramoisy D, Bourgaux P. Biochim Biophys Acta. 1998 Jan 7;1395(1):96-109.